{"id":998789,"date":"2026-08-28T08:03:55","date_gmt":"2026-08-28T12:03:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/envue-medical-inc-announces-1-for-12-reverse-stock-split\/"},"modified":"2026-08-28T08:03:55","modified_gmt":"2026-08-28T12:03:55","slug":"envue-medical-inc-announces-1-for-12-reverse-stock-split","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/envue-medical-inc-announces-1-for-12-reverse-stock-split\/","title":{"rendered":"ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split"},"content":{"rendered":"
\n

TYLER, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) — ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical technology company, today announced that a reverse stock split of the Company\u2019s issued and outstanding common stock, par value $0.001 per share (the \u201cCommon Stock\u201d) at a ratio of 1-for-12 is expected to become effective on September 1, 2026. The Company’s Common Stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on September 1, 2026, under the Company’s existing trading symbol “FEED”, but will trade under a new CUSIP number, 63008J876.<\/p>\n

After giving effect to the reverse stock split of the Company\u2019s Common Stock, each twelve (12) shares of Common Stock will be combined into one (1) share of Common Stock, such that the Company\u2019s 11,084,616 Common Stock outstanding will be reduced to approximately 923,718 shares of Common Stock outstanding (the \u201cReverse Stock Split\u201d). The Reverse Stock Split has no impact on the Company\u2019s authorized shares, which remains 40,000,000 shares of Common Stock. No fractional shares will be issued as a result of the Reverse Stock Split as any fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share on a per stockholder basis.<\/p>\n

The Reverse Stock Split was approved by the Company\u2019s board of directors under authority granted by the Company’s stockholders at the Company\u2019s Special Meeting of Stockholders held on August 14, 2026.<\/p>\n

The Reverse Stock Split will not impact any stockholder’s percentage ownership of the Company or voting power, except for minimal effects resulting from the treatment of fractional shares.<\/p>\n

All options, convertible securities including preferred stock, restricted stock (vested and unvested), restricted stock units and warrants of the Company outstanding prior to the Reverse Stock Split will be appropriately adjusted.<\/p>\n

The Reverse Stock Split will not change the number of authorized shares of preferred stock, or the par value of the Common Stock or preferred stock. After the Reverse Stock Split, the shares of the Company\u2019s Common Stock will have the same proportional voting rights and rights to dividends and distributions. VStock Transfer, LLC, will act as the exchange agent for the Reverse Stock Split. Please contact VStock Transfer, LLC for further information at (212) 828-8436.<\/p>\n

\n About ENvue Medical, Inc.<\/strong>\n <\/p>\n

ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv Israel, the Company focuses on two distinct technology platforms:<\/p>\n